LP
AUPH icon

LMR Partners’s Aurinia Pharmaceuticals AUPH Stock Holding History

LMR Partners’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-137,117
Closed -$592K – 1026
2022
Q4 		$592K Buy
137,117
+108,860
+385% +$632K 0.01% 822
2022
Q3 		$212K Sell
28,257
-27,676
-49% -$240K ﹤0.01% 1007
2022
Q2 		$562K Buy
+55,933
New +$625K 0.01% 888
2022
Q1 		– Sell
-85,593
Closed -$1.96M – 1220
2021
Q4 		$1.96M Sell
85,593
-271,117
-76% -$6.42M 0.02% 487
2021
Q3 		$7.89M Buy
+356,710
New +$5.66M 0.09% 187
2021
Q1 		– Sell
-63,633
Closed -$880K – 953
2020
Q4 		$880K Hold
63,633
– – 0.01% 298
2020
Q3 		$937K Hold
63,633
– – 0.02% 223
2020
Q2 		$1.03M Hold
63,633
– – 0.03% 355
2020
Q1 		$935K Buy
+63,633
New +$1.12M 0.04% 135

Other funds holding AUPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LMR Partners's AUPH Position: Q1 2023 in Review

LMR Partners sold out of Aurinia Pharmaceuticals (AUPH) in Q1 2023, closing a stake of 137,117 shares — an estimated $592K sold.

LMR Partners first reported a position in AUPH in Q1 2020 and held it in 9 quarters. The position peaked at $7.89M in Q3 2021. 186 funds tracked by Wall St. Rank hold AUPH as of Q1 2023.

  • LMR Partners reported no remaining Aurinia Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • LMR Partners sold 137,117 Aurinia Pharmaceuticals shares in Q1 2023, an estimated $592K.
  • LMR Partners first reported a position in Aurinia Pharmaceuticals in Q1 2020 and held it in 9 quarters.
  • LMR Partners's Aurinia Pharmaceuticals position peaked at $7.89M in Q3 2021.
  • 186 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2023.

Based on LMR Partners's 13F filing for Q1 2023, filed 15 May 2023.